CLINICAL TRIALS PROFILE FOR ACALABRUTINIB

All Clinical Trials for ACALABRUTINIB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02029443 ↗	ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1/Phase 2	2014-01-30	This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
NCT02112526 ↗	Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-08-07	To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
NCT02157324 ↗	Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-08-18	This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
NCT02180711 ↗	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	Recruiting	Acerta Pharma, LLC	Phase 1/Phase 2	2015-02-01	Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
NCT02180711 ↗	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	Recruiting	Acerta Pharma BV	Phase 1/Phase 2	2015-02-01	Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
NCT02180724 ↗	An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia	Active, not recruiting	Acerta Pharma BV	Phase 2	2014-09-08	The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.

Clinical Trial Conditions for ACALABRUTINIB

Condition Name

Condition Name for ACALABRUTINIB
Intervention	Trials
Chronic Lymphocytic Leukemia	30
Mantle Cell Lymphoma	22
Small Lymphocytic Lymphoma	13
Diffuse Large B Cell Lymphoma	6

Condition MeSH

Condition MeSH for ACALABRUTINIB
Intervention	Trials
Lymphoma	61
Leukemia, Lymphocytic, Chronic, B-Cell	44
Leukemia, Lymphoid	42
Leukemia	37

Clinical Trial Locations for ACALABRUTINIB

Trials by Country

Trials by Country for ACALABRUTINIB
Location	Trials
United States	465
Canada	41
United Kingdom	33
Poland	24
France	19

Trials by US State

Trials by US State for ACALABRUTINIB
Location	Trials
Texas	37
California	32
New York	30
Florida	24
Washington	24

Clinical Trial Progress for ACALABRUTINIB

Clinical Trial Phase

Clinical Trial Phase for ACALABRUTINIB
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	16
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ACALABRUTINIB
Clinical Trial Phase	Trials
Recruiting	60
Active, not recruiting	22
Completed	22

Clinical Trial Sponsors for ACALABRUTINIB

Sponsor Name

Sponsor Name for ACALABRUTINIB
Sponsor	Trials
AstraZeneca	46
Acerta Pharma BV	44
National Cancer Institute (NCI)	17

Sponsor Type

Sponsor Type for ACALABRUTINIB
Sponsor	Trials
Industry	115
Other	98
NIH	18